FTSE 100 today: Index edges higher; Centrica gains on Sizewell C stake
Investing.com -- Danaher (NYSE:DHR) delivered stronger-than-expected second-quarter results and lifted its full-year profit outlook. Still, the company’s shares fell over 2% in premarket trading on Tuesday.
The life sciences firm reported adjusted earnings per share (EPS) of $1.80, exceeding the consensus estimate of $1.64. Revenue for the period climbed 3.5% year-over-year to $5.94 billion, also ahead of the $5.84 billion consensus.
Operating cash flow for the quarter was $1.3 billion, while non-GAAP free cash flow came in at $1.1 billion.
"Our team’s strong execution using the Danaher Business System, paired with another quarter of robust growth in our Bioprocessing business and disciplined cost management, enabled us to exceed our expectations for the quarter," said Rainer M. Blair, President and CEO of Danaher.
"While the macro environment remains fluid, we believe the combination of our talented team, the differentiation of our portfolio, and our strong financial profile will enable us to continue generating sustainable, long-term value for shareholders for the remainder of 2025 and beyond," he added.
Looking ahead, the company expects third-quarter non-GAAP core revenue to grow at a low-single-digit rate year-over-year.
For the full year, Danaher maintained its forecast of approximately 3% growth in core revenue.
However, it raised its full-year adjusted EPS guidance to a range of $7.70 to $7.80, up from a prior range of $7.60 to $7.75. The midpoint of the new guidance is ahead of the consensus estimate of $7.70.